Skip to main content

CLEANING VALIDATION SAMPLING PROCEDURE

CLEANING VALIDATION
SAMPLING PROCEDURE

The cleaning validation is to verify the effectiveness of the cleaning procedure for removal of product residues, preservatives, excipients and cleaning agents so that the analytical monitoring may be reduced to a minimum in the routine phase. In addition one need to ensure there is no risk associated with cross contamination of active ingredients. Cleaning validation is intended to address special consideration and issues pertaining to validation cleaning procedures for equipment used in the manufactured of pharmaceutical products, radiopharmaceuticals, and biological drugs. The document is also intended to establish inspection consistency and uniformity with respect to equipment cleaning procedures.

SAMPLING PROCEDURE

In order to evaluate a cleaning method it is necessary to sample the product contact surfaces of the equipment and establish the level of residuals present.

i) Swabs and Wipes Method

Swabbing is the most widely used sampling technique. Swabs may be saturated with solvent such as water or alcohol, facilitating the solubilzation and physical removal of surface residues.


Advantages
Dissolves and physically remove sample.
Adequate to a wide variety of surfaces
Economical and widely available.
Allows sampling of a defined area.


Limitations
An invasive technique that may introduce fibers.
Results may be technique dependent.
Swab material and design may inhibit recovery and specificity of the method.
Evaluation of large, complex and hard-toreach areas difficult (e.g. crevices, pipes,     valves, large vessels). In obtaining rinse samples, location, timing and volume are important considerations.

ii) Rinse Method Advantages


Adaptable to online monitoring.
Easy to sample and non-intrusive.
Allows sampling of a large surface area.
Allows sampling of porous surfaces.
                                                                     

Limitations
Residues may not be homogeneously distributed.
Inability to detect location of residues.
Rinse volume is critical to ensure accurate interpretation of results.

iii) Coupon sampling

Coupons of the same materials of construction as the item to be cleaned can be affixed to the equipment, spiked with the product, subject to the cleaning procedures and then submitted to the laboratory for direct analysis and recovery studies.


Advantages
Allows for direct surface sampling.
Useful in cleaning method development.
Reduced variability in recovery.
Useful in evaluation of equipment materials of construction.

Limitations
Coupon may not be representative of equipment
contamination or cleaning as it is separate from
primarily surface.

Invasive
Might interfere with the cleaning process.

iv) Solvent Sampling

This technique uses a solvent not normally employed in the cleaning process to maximize
recovery residues.
Advantages
Commonly used in bulk chemical facilities
Applicable for actives, cleaning agents, excipients
Less technique dependent than swabs.
Usually affords more analytical specificity, less recovery loss than swabs. Allows sampling of a larger surface area.
Allows sampling of porous and delicate surface
Maximizes recovery to rinse.

Limitations
May require operator protection and other safety and environmental protection
measures.
May require more than one sampling for broad spectrum analysis.
Reduced physical sampling of the surface.
May be difficult to accurately define the controlled area sampled, therefore usually used for rinsing an entire piece of equipment such as a vessel.
May require the removal of solvent prior to equipment use for production.

v) Placebo and Product Sampling

Placebo sampling can be used to detects residues on equipment thorough the processing of a place to batch subsequent to the cleaning process. Product sampling is similar to placebo sampling except that it uses actual product.


Advantages
Points of product contact identical for the batch two batches
Applicable for hard to reach surfaces.
Require no additional sampling steps.

Limitations
Difficult to determine recovery
Lowers analytical specificity and inhibits detectability
Residues may not be homogenously distributed.

No direct measurement of residues on product contact surfaces.

Comments

Popular posts from this blog

DATA INTEGRITY (ALCOA ++)

 INTRODUCTION   The purpose of this guidance is to clarify the role of data integrity in current good manufacturing  practice (CGMP) for drugs, as required in 21 CFR parts 210, 211, and 212. Part 210 covers  Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of  Drugs; General; part 211 covers Current Good Manufacturing Practice for Finished  Pharmaceuticals; and part 212 covers Current Good Manufacturing Practice for Positron  Emission Tomography Drugs. This guidance provides the Agency’s current thinking on the creation and handling of data in accordance with CGMP requirements. FDA expects that data be reliable and accurate (see the “Background” section). CGMP  regulations and guidance allow for flexible and risk-based strategies to prevent and detect data  integrity issues. Firms should implement meaningful and effective strategies to manage their data  integrity risks based upon their process understanding and knowledge management of tec

PERMITTED DAILY EXPOSURE (PDE)

PERMITTED DAILY EXPOSURE (PDE) or ACCEPTANCE DAILY EXPOSURE Introduction During the manufacture of medicinal products accidental cross contamination can result from the uncontrolled release of dust, gases, vapours, aerosols, genetic material or organisms from active substances, other starting materials, and other products being processed concurrently, as well as from residues on equipment, and from operators ’ clothing. Due to the perceived risk, certain classes of medicinal product have previously been required to be manufactured in dedicated or segregated self contained facilities including, “certain antibiotics, certain hormones, certain cytotoxics and certain highly active drugs”. Until now no official guidance is available in order to assist manufacturers to differentiate between individual products within these specified classes. METHODS FOR ESTABLISHING EXPOSURE LIMITS The Gaylor-Kodell method of risk assessment (Gaylor, D. W. and Kodell, R. L.: Linea

21 Code of Federal Regulations Parts 211 Subpart K-Returned and Salvaged Drug Products

21 Code of Federal Regulations Parts 211 Subpart K-Returned and Salvaged Drug Products § 211.204 Returned drug products. Returned drug products shall be identified as such and held. If the conditions under which returned drug products have been held, stored, or shipped before or during their return, or if the condition of the drug product, its container, carton, or labeling, as a result of storage or shipping, casts doubt on the safety, identity, strength, quality or purity of the drug product, the returned drug product shall be destroyed unless examination, testing, or other investigations prove the drug product meets appropriate standards of safety, identity, strength, quality, or purity. A drug product may be reprocessed provided the subsequent drug product meets appropriate standards, specifications, and characteristics. Records of returned drug products shall be maintained and shall include the name and label potency of the drug product dosage form, lot number (or co